Correlation of Low SLC22A18 Expression with Poor Prognosis in Patients with Glioma.

Sheng-Hua Chu,Yan-Bin Ma,Dong-Fu Feng,Hong Zhang,Zhi-An Zhu,Zhi-Qiang Li,Pu-Cha Jiang
DOI: https://doi.org/10.1016/j.jocn.2011.04.032
IF: 2.116
2012-01-01
Journal of Clinical Neuroscience
Abstract:We investigated the expression of the putative tumor suppressor SLC22A18 to evaluate it as a prognostic marker in glioma patients. Immunohistochemical and Western blot analyses of clinical tissue samples obtained from 120 patients with glioma were performed. Low expression of SLC22A18 was observed in 71.7% of patients. Loss of SLC22A18 expression in glioma was significantly related to pathological grade (p=0.003). High pathological grade (World Health Organization III–IV) was correlated with negative (low or absent) expression of SLC22A18, which was correlated with a significantly shorter overall patient survival than in those with positive (high) expression (p=0.007). Multivariate Cox regression analysis indicated that SLC22A18 expression level is an independent survival prognostic factor for patients with glioma (p=0.011). Western blotting analysis confirmed decreased expression of SLC22A18 in glioma tissues compared with adjacent brain tissues. This study suggests that SLC22A18 functions as a tumor suppressor in glioma and represents a candidate biomarker for long-term survival in this disease.
What problem does this paper attempt to address?